Boryung announced on the 3rd that it has launched the multiple myeloma treatment drug 'Pomalin capsule.'
Pomalin is the first generic anti-cancer drug in South Korea containing the ingredient 'pomalidomide' and is available in four dosages: 1 mg, 2 mg, 3 mg, and 4 mg. Among the pomalidomide generics approved in South Korea, Pomalin is the only drug with the same indications, administration route, ingredients, and form. It has ensured biological equivalence with the original medicine as well as the safety of the raw materials. Boryung used verified raw materials that are registered under both the Ministry of Food and Drug Safety and the U.S. Food and Drug Administration's (FDA) raw material registration system.
Pomalin is used to treat the blood cancer multiple myeloma. It can be used in combination with bortezomib and dexamethasone for patients with multiple myeloma who have been treated with one or more therapies, including lenalidomide. For patients who have relapsed or shown no effect after receiving at least two types of treatment including lenalidomide and bortezomib, it can also be used along with dexamethasone.
With the launch of Pomalin, Boryung has established a portfolio of seven blood cancer drugs. Boryung is the only company operating a blood cancer group in South Korea. Kim Young-seok, Boryung's head of Commercial Excellence institutional sector, noted, "We will continue to develop generic anti-cancer drugs to expand treatment options for cancer patients," and "We will ensure a stable supply of essential anti-cancer drugs to enhance patients' health rights."